Treatment Difficulties in High Risk Pulmonary Embolism. A Case Report
References
- 1. Goldhaber SZ. Pulmonary Embolism. N Engl J Med. 1998;339:93-104.
- 2. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med. 2002;347:1131-1132. doi:10.1016/0033-0620(91)90009-B.
- 3. Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol. 2006;97:127-129. doi: http://dx.doi.org/10.1016/j.amjcard.2005.07.117.
- 4. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right ventricular function and pulmonary perfusion. Lancet. 1993;341:507-511. doi:10.1016/0140-6736(93)90274-K.
- 5. Konstantinides S, Tiede N, Kasper W, et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol. 1998;82(8):966-970. doi: http://dx.doi.org/10.1016/S0002-9149(98)00513-X.
- 6. Fukuda I, Taniguchi S, Suzuki Y, et al. Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg. 2011;91(3):728-732. doi: 10.1016/j.athoracsur.2010.10.086.
- 7. Kuo WT, Gould MK, Hofmann LV, et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009;20(11):1431-1440. doi: 10.1016/j. jvir.2009.08.002.
- 8. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet. 1960;1(7138):1309-1312.
- 9. Kanter DS, Mikkola KM, Goldhaber SZ, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111(5):1241-1245. doi:10.1378/chest.111.5.1241
- 10. Levine MN, Goldhaber SZ, Califf RM, et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest. 1995;108(4 Suppl):291S-301S.
- 11. Mikkola KM, Patel SR, Goldhaber SZ, et al. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J. 1997;134(1):69-72. doi: http://dx.doi.org/10.1016/S0002-8703(97)70108-X.
- 12. Sharifi M, Bay C, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol. 2013;111(2):273-7. doi: 10.1016/j.amjcard.2012.09.027.
- 13. Wang C, Zhai Z, Shen YH, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest. 2010;137(2):254-62. doi: 10.1378/chest.09-0765.
- 14. Engelberger RP, Kucher N, et al. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. Eur Heart J. 2014;35:758-764. doi: http://dx.doi.org/10.1093/eurheartj/ehu029.
- 15. Kucher N, Boekstegers P, Baumgartner I, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circ. 2014;129(4):479-86. doi: 10.1161/CIRCULATIONAHA.113.005544.
Language: English
Page range: 37 - 42
Submitted on: Oct 15, 2015
Accepted on: Jan 17, 2016
Published on: Jun 3, 2016
Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2016 Balázs Bajka, Edvin Benedek, Alexandra Stănescu, Emese Rapolti, Monica Chițu, István Kovács, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.